Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : LTX-002
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Chugai Venture Fund
Deal Size : $45.0 million
Deal Type : Financing
Leal Secures $45M to Advance Neurodegenerative And Psychiatric Therapies
Details : The proceeds will be used to advance Leal's pipeline of ASO lead programs, which includes LTX-002 for the treatment of patients with genetic or sporadic amyotrophic lateral sclerosis.
Brand Name : LTX-002
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 30, 2024
Lead Product(s) : LTX-002
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Chugai Venture Fund
Deal Size : $45.0 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?